SenGenix Inc., a biotechnology company trying to revolutionize blood tests, raised $6.2 million according to a filing Monday with the Securities and Exchange Commission.

The company, founded in a lab at Duke University, obtained the money from 18 investors, according to the filing.

SenGenix raised the money in the form of equity, but it did not disclose what it intends to do with the offering.

The money will not be used to pay executive officers, promoters or directors outside the payment of normal salaries and other compensation and benefits.

The Durham-based company is developing point-of-care tests based on fluorescently responsive sensors that SenGenix intends to create a fast, accurate and actionable patient data at a low cost, according to its website.

The company raised a total of $4.9 million in three previous rounds of funding over the past three years.

Dr. Richard S. Surwit, the chief executive officer of SenGenix, is a professor of psychiatry and behavioral sciences and the former vice chairman for research in the Department of Psychiatry at Duke University.

He is the founder and chairman of ZyCare, Inc., a provider of personnel supply services, and holds six U.S. patents.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must first file what’s known as a Form D electronically with the SEC after they first sell their securities.